Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals
COPENHAGEN, Sept 16 (Reuters) - Danish pharmaceutical company Lundbeck LUN.CO will acquire Alder BioPharmaceuticals ALDR.O in a deal valued at almost $2 billion, the company said in a statement on Monday.
The deal, expected to close in the fourth quarter of this year, will be funded through existing cash resources and bank financing, Lundbeck said.
Alder develops preventative treatments of migraine in adults and has submitted a Biologics License Application for its eptinezumab antibody to the FDA in February this year.
Lundbeck will buy outstanding shares of Alders in an upfront payment of $18 per share.
The board of Alders has approved the transaction unanimously.
(Reporting by Nikolaj Skydsgaard Editing by Shri Navaratnam)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest US Markets Videos
- Dashboard of a Downturn: Coronavirus Starts To Set Off Some Recession Alarm Bells
- Security contractor G4S to sell most of cash ops to Brinks in $945 million deal
- U.S. Consumer Spending Could See One-Two Punch From Stocks Drop, Coronavirus
- EXCLUSIVE-SmileDirectClub’s top dentist risks losing license in California crackdown